PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA

Anka Poštić1, Marijana Virijević2,3

1 Clinic for Pulmonology, Clinical Center of Serbia, Belgrade, Serbia
2 Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia
3 Faculty of Medicine, University of Belgrade, Belgrade, Serbia

SAŽETAK

Uvod: Akutna mijeloidna leukemia (AML) predstavlja patološku proliferaciju če- lijaja mijeloidne loze. Predominantno se javlja kod pacijenata starijih od 60 godina, sa značajno lošijim ishodom lečenja u poređenju sa mlađima.

Cilj: Cilj rada bio je da se izvrši analiza kliničkih karakteristika starijih bolesnika sa AML-om, kao i uticaj tih karakteristika na: postizanje kompletne remisije (KR), ukupno preživljanje (engl. early mortality – EM), i recidiv bolesti.

Materijal i metode: Ovo je retrospektivna studija koja je obuhvatala 94 pacijen- ta sa AML-om, nakon primene hemioterapije i palijativne terapije, u kojoj su rezultati pronađeni. U analizu su uključeni pacijenti stariji od 60 godina. Uzeti su u obzir kliničke znakove, izražene kao faktor rizika za osnovne kriterije. Analiza je radila na identifikaciji progno- stičkih faktora.

Rezultati: Prosječna starost pacijenata iznosila je 69 godina (opseg: 65 – 87). KR je postigla 23 (46%) od 50 pacijenata (53,2%) koji su imali intenzivnu hemioterapiju, pri čemu je do relapsa došlo kod 17/23 pacijenata (73,9%). EM je zabeležena kod 17 pacijenata (18.1%). Pacijenti sa ECOG PS > 2 imali su statistički značajno lošije OS u odnosu na pacijente sa ECOG PS < 2 (p = 0.030). Pacijenti sa HCT-CI > 3 imali su lošije OS u odnosu na pacijente sa HCT-CI < 3 (p = 0.040). Nivo LDH > 450 U/I pokazao je kao loš prognoštni faktor za OS u odnosu na LDH < 450 U/I (p = 0.044).

Zaključak: Zaključak je da stariji pacijenti sa AML-om, koji imaju lošije funkcionalno stanje prema ECOG, vode u odnosu na KR, recidiv bolesti i EM.

Ključne reči: akutna mijeloidna leukemia, stariji pacijenti, ukupno preživljava- nje, prognoštni faktori

ABSTRACT

Introduction: Acute myeloid leukemia (AML) is characterized by pathological proliferation of myeloid lineages. It predominantly occurs in patients over 60 years of age, whose outcome is considerably worse, as compared to younger patients.

Aim: The aim of the study was the analysis of the clinical characteristics of older patients with AML and their impact on the following: achieving complete remis- sion (CR), overall survival (OS), early mortality (EM), and relapse.

Materials and methods: This retrospective study included 94 patients with AML, treated with chemotherapy and palliative treatment, whose information was taken from their medical histories, upon treatment. The following clinical features were analyzed as risk factors for OS, CR, relapse and EM: leukocytes, the level of se- rum lactate dehydrogenase (LDH), performance status on the ECOG (Eastern Coop- erative Oncology Group) scale, the European LeukemiaNet cytoplasmic risk group, the HCT-CI (hematopoietic cell transplantation - comorbidity index) and the NPM1/FLT3-ITD (nucleophosmin 1/FLT3-internal tandem mutation) molecular status.

For the identification of prognostic factors, the Cox regression analysis was used.

Results: The average age of the patients was 69 years (range: 65 – 87). CR was achieved in 23 (46%) of the 50 patients (53.2%) who received intensive chemotherapy, with relapse occurring in 17/23 patients (73.9%). EM was reported in 17 patients (18.1%). Patients with ECOG PS ≥ 2 had a statistically significantly lower OS than patients with ECOG PS < 2 (p = 0.030). Patients with HCT-CI ≥ 3 had a poorer OS than patients with HCT-CI < 3 (p = 0.040). Serum LDH > 450 U/I was found to be a factor, i.e., marker of unfavorable prognosis for the OS, as compared to LDH < 450U/I (p = 0.044).

Conclusion: The conclusion is that older AML patients with poorer ECOG PS, high HCT-CI, increased LDH levels have a poorer OS.

Key words: acute myeloid leukemia, elderly patients, overall survival, progno- stic factors
UVOD

Acute leukemias (AL) are malignant clonal diseases of the hematopoietic stem cell, occurring due to anomaly in the stem cell genome, and resulting in uncontrolled proliferation and infiltration of different tissues [1].

Acute myeloid leukemia (AML) is characterized by pathological proliferation of the cells of the myeloid lineage [1]. AML is a disease predominantly affecting patients above the age of 60 years, i.e., elderly patients [2-4]. The incidence of AML in patients older than 75 years is more than 15 per 100,000 population, while the incidence of this disease in patients younger than 40 years is approximately 4 per 100,000 population [5,6].

The outcome of AML treatment is significantly poorer in elderly patients, as compared to patients younger than 60 years [7,8]. An unfavorable outcome in elderly patients is connected to numerous factors, which can be connected to AML itself, or related to the individual characteristics of the patient [8]. The factors believed to affect the unfavorable outcome of AML treatment in elderly patients, which are related to the individual characteristics of the patients, are the following: existing comorbidities, pharmacodynamic features, organ function weakening due to old age, weaker response to systemic bacterial and fungal infections - as a result of the weakened function of the immune system, as well as poorer general performance status assessed with the ECOG (Eastern Cooperative Oncology Group) scale. On the other hand, markers, i.e., factors predicting an unfavorable outcome in acute myeloid leukemia in elderly patients, which are related to the disease itself, are the following: higher incidence of secondary AML and AML developing after the application of cytotoxic therapy, as well as a less favorable genetic mutation profile, which is all related to resistance to treatment [7-9,11].

Also, elderly patients are worse at tolerating standard intensive treatment, which is why less intensive and palliative treatment are frequently resorted to [10-12]. Early mortality during standard intensive treatment is one of the reasons of unfavorable outcome in the treatment of elderly patients with this form of therapy [11].

However, results showing the prognosis of elderly patients with AML in many available studies, are not frequently presented, due to selection bias in most of these studies, wherein very old and high-risk patients are excluded from the analysis [8,11].

The aim of the study was the analysis of the clinical characteristics of older patients with AML, and their impact on the following: achieving complete remission (CR), overall survival (OS), early mortality (EM), and relapse.

MATERIJALI I METODE

Istraživanje je sprovedeno u vidu retrospektivne studije na osnovu baze podataka Klinike za hematologiju, Kliničkog Centra Srbije, a uključilo je 94 pacijenta sa AML-om, starijih od 65 godina, koji su pristrasnosti većine studija da izbacuju veoma stare i visoko rizične pacijente [8,11].

Rana smrtnost u toku standardne intenzivne terapije, zbog manje intenzivne ili palijativne terapije [10-12].

Ishod lečenja AML-a je značajno lošiji kod starijih pacijenata, u odnosu na pacijente mlađe od 60 godina [7,8]. Loš ishod kod starijih pacijenata povezan je sa mnogoobrojnim faktorima, koji mogu biti vezani za samu bolest – AML, ili se odnose na samog pacijenta [8]. Faktori, za koje se smatra da utiču na loš ishod terapije AML-a, kod starijih, a odnose se na same pacijente su: komorbiditeti, farmakodinamske osobine, smanjenje funkcija organa usled starosti, slabiji odgovor na sistemske bakterijske i gljivice infekcije usled slabije funkcije imunog sistema, kao i lošije opšte funkcionalno stanje procenjeno prema ECOG (Eastern Cooperative Oncology Group) skali. Sa druge strane, loši prognostički faktori kod akutne mijelodine leukemije, kod starijih pacijenata, koji se odnose na samu bolest, jesu: veća zastupljenost sekundarnih AML-a i AML-a nastalih po sekundarnoj proliferaciji i infiltraciji različitih tkiva [1].

Međutim, rezultati koji pokazuju prognozu starijih pacijenata sa AML-om u mnogim dostupnim studijama, nisu u tolikoj meri zastupljeni, zbog selektivne prisutnosti većine studija da izbacuju veoma stare i visoko rizične pacijente [8,11].

Cilj ovog rada bila je analiza kliničkih karakteristika kod starijih bolesnika sa AML-om i analiza njihovog uticaja na: postizanje kompletne remisije (KR), ukupno preživljavanje, ranu smrt, i recidiv bolesti.

INTRODUCTION

Acute leukemias (AL) are malignant clonal diseases of the hematopoietic stem cell, occurring due to anomaly in the stem cell genome, and resulting in uncontrolled proliferation and infiltration of different tissues [1].

Acute myeloid leukemia (AML) is characterized by pathological proliferation of the cells of the myeloid lineage [1]. AML is a disease predominantly affecting patients above the age of 60 years, i.e., elderly patients [2-4]. The incidence of AML in patients older than 75 years is more than 15 per 100,000 population, while the incidence of this disease in patients younger than 40 years is approximately 4 per 100,000 population [5,6].

The outcome of AML treatment is significantly poorer in elderly patients, as compared to patients younger than 60 years [7,8]. An unfavorable outcome in elderly patients is connected to numerous factors, which can be connected to AML itself, or related to the individual characteristics of the patient [8]. The factors believed to affect the unfavorable outcome of AML treatment in elderly patients, which are related to the individual characteristics of the patients, are the following: existing comorbidities, pharmacodynamic features, organ function weakening due to old age, weaker response to systemic bacterial and fungal infections - as a result of the weakened function of the immune system, as well as poorer general performance status assessed with the ECOG (Eastern Cooperative Oncology Group) scale. On the other hand, markers, i.e., factors predicting an unfavorable outcome in acute myeloid leukemia in elderly patients, which are related to the disease itself, are the following: higher incidence of secondary AML and AML developing after the application of cytotoxic therapy, as well as a less favorable genetic mutation profile, which is all related to resistance to treatment [7-9,11].

Also, elderly patients are worse at tolerating standard intensive treatment, which is why less intensive and palliative treatment are frequently resorted to [10-12]. Early mortality during standard intensive treatment is one of the reasons of unfavorable outcome in the treatment of elderly patients with this form of therapy [11].

However, results showing the prognosis of elderly patients with AML in many available studies, are not frequently presented, due to selection bias in most of these studies, wherein very old and high-risk patients are excluded from the analysis [8,11].

The aim of the study was the analysis of the clinical characteristics of older patients with AML, and their impact on the following: achieving complete remission (CR), overall survival (OS), early mortality (EM), and relapse.
dijagnostikovani i lečeni u periodu od novembra 2013. do novembra 2018.

Kod bolesnika su, pri dijagnozi, evidentirane demografiske i kliničko-laboratorijske karakteristike: pol, starost, opšte funkcionalno stanje prema ECOG skali [13], kompletna krvena slika (hemoglobin, broj leukocita, trombocita, leukocitarna formula), nivo serumskih laktat dehidrogenaze (LDH), procenat blasta u perifernoj krvi i koštanoj srži. Procena komorbiditeta je vršena na osnovu komorbiditetnog indeksa (engl. hematopoietic cell transplantation-comorbidity index (HCT-CI)) koji se koristi za transplantaciju matičnih čelija hematopoeze [14]. Citogenetski stepen rizika određen je prema preporukama međunarodnog ekspertskog panela za lečenje akutne bolesti mađar i koštanog krvnog formiranja (HCT-CI) ≥ 3, ECOG ≤ 2, HCT-CI < 3.

1. Immunofenotipizacija protočnom citometrijom, metodom direktna višekolorne imunofluorescencije [17];
2. Klasična citogenetska analiza, metodom HG traka, prema Međunarodnom sistemu za humanu citogenetsku nomenklaturu [18];
3. Molekularno-genska istraživanja – testirana je prisutnost genskih mutacija – nukleosphin/FLT3-internal tandem mutations (NPM1/FLT3-ITD).

U okviru hematološke dijagnostike učinjena je:
1. Citološka analiza – obavljena je na razmazima koji su bojeni Mej-Grinwald- Gimza (MGG) metodom, uz dopunsku bojenja (MPO, SBB, PAS, NSE);
2. Klasična citogenetska analiza, metodom HG traka, prema Međunarodnom sistemu za humanu citogenetsku nomenklaturu [18];
4. Molekularno-genska istraživanja – testirana je prisutnost genskih mutacija – nukleosphin/FLT3-internal tandem mutations (NPM1/FLT3-ITD).

Pacijenti su lečeni hemoterapijskim protokolima za bolesnike starije od 60 godina, u skladu sa ECOG preporukama [15]. U zavisnosti od ECOG i HCT-CI, primenjena je intenzivna hemoterapija, terapija niskog intenziteta ili palijativna terapija. Hemoterapiju visokog intenziteta primili su pacijenti koji su imali ECOG ≤ 2, HCT-CI < 3 po šemi ‘3+7 light’, u sastavu: daunorubicin – u dozi od 45 mg/m² na dan 1, 2, 3, u kombinaciji sa citorabinom – u dozi od 100 mg/m² dnevno, kontinuirano intravenoskom (iv) infuzijom, 7.dana. Pacijenti koji su imali ECOG > 2, HCT-CI ≥ 3, lečeni su po šemi ‘2+5’, u sastavu: daunorubicin – u dozi 100 mg/m² iv D 1, 3, i citorabin – u dozi 100 mg/m² iv kontinuirano D 1-5.

Hemoterapija niskog intenziteta primenjena je kod pacijenta sa ECOG > 2, HCT-CI ≥ 3, koji nisu bilo nepovoljnog citogenetskog rizika prema ECOG klasiifikaciji. Podrazumevala je primenu manjih doza citorabina (20 mg, s.c., na 12 h, D 1-10), i monoterapiju vezidom am. 100 mg D 1-5. Palijativna terapija se sastojala iz primene citoreduktivnih terapija (Litalir kapsule) i supportive terapije, u vidu primene transfuzije derivata krvi. Primjenjena je kod pacijenta koji nisu mogli da toleriru nikakvu antileukemiju terapiju, ili nisu želeli da se leče.

MATERIALS AND METHODS

This is a retrospective study carried out on the basis of the database of the Clinic for Hematology of the Clinical Center of Serbia, which included 94 patients with AML, older than 65 years, who were diagnosed and treated in the period between November 2013 and November 2018.

The following demographic, clinical and laboratory characteristic of the patients were recorded at diagnosis: sex, age, general performance status according to the ECOG scale [13], complete blood count (hemoglobin, white blood cell count, platelet count, WBC differential), level of serum lactate dehydrogenase (LDH), and the percentage of blasts in peripheral blood and bone marrow. The assessment of comorbidities was performed on the basis of the hematopoietic cell transplantation-comorbidity index (HCT-CI), used in hematopoietic stem-cell transplantation [14]. The cytogenetic risk level was determined on the basis of the recommendations of an international leukemia expert panel, given on behalf of European LeukemiaNet (ELN) [15].

The following was performed as part of the hematological diagnostics:

1. Cytological analysis – performed on smears stained with the use of the May-Grünwald Giemsa (MGG) method, with additional staining (MPO, SBB, PAS, NSE);
2. Immunophenotypization by means of flow cytometry with the use of the direct multicolor immunofluorescence method [17];
3. Classical cytogenetic analysis with the application of the HG-banding technique, in keeping with the International System for Human Cytogenetic Nomenclature [18];
4. Molecular genetic research - patient bone marrow was tested for the presence of genetic mutations - nukleosphin/FLT3-internal tandem mutations (NPM1/FLT3-ITD).

Patients were treated with chemotherapeutic protocols for patients older than 60 years, in keeping with ELN recommendations [15]. Depending on the ECOG and HCT-CI, intensive chemotherapy, low-intensity therapy, or palliative treatment were applied. Patients with ECOG ≤ 2, HCT-CI < 3 received high-intensity chemotherapy, patients with ECOG > 2, HCT-CI ≥ 3, were treated under the ‘2+5’ regimen, which included: daunorubicin – in the dosage of 45 mg/m² per day 1, 2, 3 in combination with cytarabine – in the dosage of 100 mg/m² per day, continuously via iv infusion, for 7 days. Patients with ECOG > 2, HCT-CI ≥ 3, were treated under the ‘2+5’ regimen, which included: daunorubicin – in the dosage of 30 mg/m², iv, D 1, 3, and citorabine – in the dosage of 100 mg/m², iv, continuously, D 1-5.
Procena efikasnosti lečenja sprovedena je na kraju indukcionog lečenja prema opšte prihvaćenim kliničkim kriterijumima Međunarodne radne grupe za AML [19]. Pod refraktornom bolešću podrazumeva se nepostizanje KR, za pacijente koji su preživeli ≥ 7 dana od završetka indukcije. Ukupno preživljavanje (engl. overall survival – OS) je definisano kao vreme proteklo od dijagnoze do smrti ili datumu poslednjeg praćenja. Rana smrt je definisana kao smrt u periodu od 28 dana od otpočinjanja indukcione hemioterapije [20].

Statištika analiza rađena je pomoću podataka iz otpusnih lista uzetih iz Registara Klinike za hematologiju, Kliničkog centra Srbije, korišćenjem programa Microsoft Excel. Zavisno od tipa varijabli i normalnosti raspodele, deskripcija podataka prikazana je kao n (%) ili medijana (opseg, min-max). Za pronalaženje nezavisnog prediktora smrtnog ishoda kod starijih bolesnika sa AML-om primenjen je univarijantni Koksov regresioni model sa 95%-tim intervalom poverenja. Statištčke hipoteze su testirane na nivou statističke značajnosti (alpha nivo) od 0,05.

REZULTATI

Istraživanjem je obuhvaćeno 94 pacijenta, od toga 56 muškaraca (59,6%) i 38 žena (40,4%). Prekočna starost pacijenata iznosila je 69 godina (opseg: 65 – 87 godina). Starijih od 70 godina bilo je 36/94 pacijenata (38,3%), dok je najveći broj, 58 bolesnika (61,7%), bio starosti između 65 i 70 godina.

Pри диганозе, већи број болнiha, њих 49 (53,3%), bio je доброг општог функционалног стања, ECOG skor < 2, dok je 43 bolesnika (46,81%) имало ECOG skor ≥ 2.

Visok HCT-CI skor ≥ 3, при диганозе је имало 26 па-

Prema vrednostima LDH u serumu, pacijenti су kla-

Prema vrednostima LDH u serumu, pacijenti су kla-

Pacijenata sa brojem leukocita Le < 30x109/l bilo je 66 (71%), dok je pacijenata sa vrednostima Le > 30x109/l bilo 27 (29%).

Pacijenta sa de novo AML-om je bilo 81 (86,2%), dok je slučajeva sekundarnih AML-a, kao transformacija druge hematološke bolesti, bilo je 13 (13,8%).

NPM1/FLT3-ITD status određen je kod 19/94 pacijenata, od kojih je sa NPM1-/FLT3-ITD- statusom bilo 15 pacijenata (78,9%), a NPM1+/FLT3-ITD- status je imalo 4 pacijenta (21,1%).

Low-intensity chemotherapy was applied in pa-

The study included 94 patients, 56 men (59.6%) and 38 women (40.4%). The average age of the patients was 69 years (range: 65 – 87 years). There were 36/94 patients older than 70 years (38.3%), while the largest number of patients, 58 (61.7%), were between 65 and 70 years old.

More patients, 49 of them (53.3%), had a good per-

At diagnosis, 26 patients (28.6%) had a high HCT-CI score ≥ 3, while 65 patients (71.4%) had an HCT-CI score < 3.

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

Low-intensity chemotherapy was applied in pa-

The assessment of treatment efficacy was made at

The disease is considered refractory if CR has not been achieved, in patients who survived ≥ 7 days after the completion of induction therapy. Overall survival (OS) is defined as the time that has elapsed from diagnosis until death or until the day of the last follow-up. Early mortality is defined as death within 28 days of the initiation of induction che-

Thomas Working Group for AML [19]. The disease is considered refractory if CR has not been achieved, in patients who survived ≥ 7 days after the completion of induction therapy. Overall survival (OS) is defined as the time that has elapsed from diagnosis until death or until the day of the last follow-up. Early mortality is defined as death within 28 days of the initiation of induction chemotherapy [20].

Statistical analysis was performed on the basis of
data found in patient discharge papers taken from the Records of the Clinic for Hematology of the Clinical Center of Serbia, with the use of Microsoft Excel. Depending on the types of variables and the normality of distribution, the description of data is presented as n (%) or the median value (range, min-max). The univariate Cox regression model with a 95% confidence interval was used for finding the independent predi-

carriage of cytogenetic risk, to the ELN classification, was not unfavorable. This therapy involved the administration of low doses of cytarabine (20 mg, SC, per 12 h, D 1-10), and monotherapy with VePesid infusion vials, 100 mg, D 1-5. Palliative treatment included administering cyto-

terative therapy (Lilital capsulif) and supportive therapy, in the form of the transfusion of blood prod-

Low-intensity chemotherapy was applied in pa-

The assessment of treatment efficacy was made at

The disease is considered refractory if CR has not been achieved, in patients who survived ≥ 7 days after the completion of induction therapy. Overall survival (OS) is defined as the time that has elapsed from diagnosis until death or until the day of the last follow-up. Early mortality is defined as death within 28 days of the initiation of induction che-

Thomas Working Group for AML [19]. The disease is considered refractory if CR has not been achieved, in patients who survived ≥ 7 days after the completion of induction therapy. Overall survival (OS) is defined as the time that has elapsed from diagnosis until death or until the day of the last follow-up. Early mortality is defined as death within 28 days of the initiation of induction chemotherapy [20].

Statistical analysis was performed on the basis of
data found in patient discharge papers taken from the Records of the Clinic for Hematology of the Clinical Center of Serbia, with the use of Microsoft Excel. Depending on the types of variables and the normality of distribution, the description of data is presented as n (%) or the median value (range, min-max). The univariate Cox regression model with a 95% confidence interval was used for finding the independent predi-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-

According to the ELN cytogenetic and molecular risk level classification, 5 patients (5.3%) had a favor-
Prognostic factors in elderly patients with acute myeloid leukemia

Patients were classified, according to the level of serum LDH, in the LDH < 450 U/l group, with 56 patients (60.9%), and the LDH ≥ 450 U/l group, with 36 patients (39.1%).

There were 66 patients (71%) whose WBC count (Le count) was Le < 30x10⁹/l, while 27 patients (29%) had a leukocyte count of Le > 30x10⁹/l.

There were 81 (86.2%) patients with de novo AML, while 13 cases (13.8%) were secondary AML, occurring as a transformation of a different hematological disease.

NPM1/FLT3-ITD status was determined in 19/94 patients, of whom 15 patients (78.9%) had an NPM1-/FLT3-ITD- status, while 4 patients (21.1%) had an NPM1+/FLT3-ITD- status.

The percentage of blasts in peripheral blood (PB) < 50% was present in 73 patients (80.2%), while the percentage of blasts in PB > 50% was present in 18 patients (19.8%). The percentage of blasts in bone marrow < 50% was present in 43 patients (46.7%), while the percentage of blasts in bone marrow > 50% was present in 49 patients (53.3%).

Of a total of 50 patients (53.2%) in the study who had received intensive chemotherapy, complete remission (CR) was achieved by 23 patients (46%).

Relapse occurred in 17 patients (73.9%) who had achieved CR. The median duration of CR was 7 months (range: 1 – 24).

Early mortality was registered in 17 patients (18.1%) involved in the study.

The median overall survival of AML-NK patients was three months (0.1 – 38 months), two-year OS was 5.3%, while median overall survival without signs of illness was 8 months. Throughout the duration of the study a total of 89 patients (94.7%) died (Figure 1).

Univariate Cox analysis revealed factors significant for patient OS, namely: ECOG PS, HCT-CI, and LDH. Patients with ECOG PS > 2 had statistically significantly
Do relaupa je došlo kod 17 pacijenata (73,9%) koji su postigli KR. Medijana trajanja KR je bila 7 meseci (opseg: 1 – 24).

Rana smrtnost registrovana je kod 17 pacijenata (18,1%) u studiji.

Medijana preživljavanja pacijenata obolelih od AML-NK-a je bila tri meseca (0,1 – 38 meseci), dvogodišnji OS je bio 5,3%, dok je medijana preživljavanja bez znakova bolesti bila 8 meseci. Tokom studijskog perioda umrlo je ukupno 89 bolesnika (94,7%) (Grafikon 1).

Univerzitarna Koksova analiza je pokazala faktore značajne za OS pacijenata, i to su: ECOG PS, HCT-CI i LDH. Pacijenti sa ECOG PS ≥ 2 imali su statistički značajno lošije OS u odnosu na pacijente sa ECOG PS < 2 (p = 0,030). Takođe, pacijenti iz grupe sa HCT-CI ≥3 imali su lošije OS u odnosu na pacijente iz grupe sa HCT-CI < 3 (p = 0,040). Serumski nivo LDH ≥ 450 U/I pokazao se kao loš prognostički faktor za OS u odnosu na LDH < 450 U/I (p = 0,044) (Tabela 1).

Nijedan od navedenih parametara nije bio statistički značajan prediktor postizanja KR, pojave recidiva i rane smrtnosti (p > 0,05).

DISKUSIJA

Studije koje ispituju uticaj prognostičkih faktora kod starijih bolesnika imaju stroge kriterijume za uključivanje pacijenata, tako da mali broj pacijenata sa velikim brojem mogućih udruženih faktora rizika biva uključen u te studije [8,11]. Takođe, stariji pacijenti oboleli od akutne miješodljive leukemije, koji su uključivali u studije ovog tipa zbog brzog tokra bolesti i značajnih komorbiditeta, su uglavnom imali smrtni ishod pre procene odgovora na terapiju [7,11,21]. U našoj studiji smrtni ishod imalo je 89 pacijenata (94,7%), a poveljan 5 pacijenata (5,3%), što je u saglasnosti sa podacima iz literature [24].

Bolest se približno jednako javlja i kod muškaraca i kod žena (59,6% naspram 40,4%), kako u našoj studiji, tako i u literaturi [9]. Uticaj pola, kao faktora koji utiče na starije bolesnike, nije dokazan i u literaturi [9]. Uticaj pola, kao faktora koji utiče na starije bolesnike, nije dokazan i u literaturi [9]. Uticaj pola, kao faktora koji utiče na starije bolesnike, nije dokazan i u literaturi [9]. Uticaj pola, kao faktora koji utiče na starije bolesnike, nije dokazan i u literaturi [9]. Uticaj pola, kao faktora koji utiče na starije bolesnike, nije dokazan i u literaturi [9].

Prosečna starost pacijenata uključenih u našu studiju iznosila je 69 godina (opseg: 65 – 87). Najviše pacijenata bilo je u grupi starosti od 65 do 70 godina (61,7%).

U prospektivnoj AML96 studiji, koja je obuhvatila 909 pacijenata obolelih od akutne miješodljive leukemije, starosti 61 – 87 godina, prosečna starost obolelih je iznosila 67 godina [9]. Starost od preko 70 godina, kao pojedinačni prognostički faktor u ishodu AML-a, nije dokazan kao statistički značajan parametar (p = 0,734) u ovoj studiji, dok podaci u literaturi govore suprotno [8]. U AML96 studiji, dokazano je da starost od preko 65 godina ima statistički značajan uticaj na kraće OS [9].

lower OS, as compared to patients with ECOG PS < 2 (p = 0,030). Also, patients from the HCT-CI > 3 group had a lower OS, as compared to patients from the HCT-CI < 3 group (p = 0,040). The serum level of LDH > 450 U/I proved to be a marker of unfavorable prognosis for OS, as compared to LDH < 450 U/I (p = 0,044) (Table 1).

None of the abovementioned parameters was a statistically significant predictor for the following: achieving CR, the occurrence of relapse, early mortality (p > 0,05).

DISCUSSION

Studies analyzing the effect of prognostic factors, i.e., markers in elderly patients have strict inclusion criteria, which is why a small number of patients with a large number of possible associated risk factors are included in these studies [8,11]. Also, elderly patients suffering from acute myeloid leukemia, included in this type of study, usually had a lethal outcome before assessment on the response to treatment could be made, due to a rapid progression of the illness and significant comorbidities [7,11,21]. In our study, 89 patients (94.7%) had a lethal outcome, while 5 patients (5.3%) had a favorable outcome, which is in keeping with the data available in literature [24].

The disease occurs approximately equally in both men and women (59,6% versus 40,4%), not only in our study, but in literature as well [9]. The effect of the sex of the patient, as a factor influencing OS, CR, early mortality, or relapse of the illness, has not been proven.

The average age of the patients included in our study was 69 years (range: 65 – 87). Most of the patients belonged to the 65 – 75 age group (61,7%).

In the prospective AML96 study, which included 909 patients suffering from acute myeloid leukemia, aged 61 – 87 years, the average age was 67 years [9]. Age above 70 years, as an individual prognostic factor in the outcome of AML, was not proven as a statistically significant parameter (p = 0,734) in this study, while data from literature state the opposite [8]. The AML96 study demonstrated that age above 65 years had a statistically significant effect on shorter OS [9].

The average age of the patients with AML included in a multicentric Italian study, which covered 1,005 patients, was 69 years. The study analyzed the effect of intensive and non-intensive treatment on the overall survival of elderly patients and did not demonstrate better survival in patients treated with intensive chemotherapy. A smaller number of patients older than 70 years, as compared to younger patients, received intensive therapy, which lead to an unfavorable outcome [8].

In other studies, which analyzed the prognostic markers related to the outcome of AML in elderly patients,
Prosečna starost pacijenata sa AML-om uključenih u multicentričnu italijansku studiju koja je obuhvatala 1.005 pacijenata, bila je 69 godina. Studija je analizirala uticaj intenzivne i ne-intenzivne terapije na preživljavanje starijih pacijenata, i nije pokazala da su bolje preživljavanje imali pacijenti koji su lečeni intenzivnom hemoterapijom. Manji broj pacijenata starijih od 70 godina je, u odnosu na mlade pacijente, primio intenzivnu terapiju, što je dovelo do lošeg ishoda [8].

U drugim studijama koje su se bavile analizom prog nostičkih faktora na ishod AML-a kod starijih pacijenata, dokazan je uticaj nepovoljnog ECOG PS na veću smrtnost, postizanje KR i kraće OS, kod pacijenata starijih od 65 godina [7,11]. U našoj studiji je podaci pokazali da je ECOG PS imao statistički značajan uticaj na pojavu rane smrti (p = 0,030). Uticaj ECOG PS na postizanje KR, ranu smrtnost i pojavu relapsa nije dokazan u našoj studiji. U studiji Sout eastern Oncology Group (SWOG) koja se analizirani pacijenti starosti ≥ 56 godina pokazan je značajan uticaj nepovoljnog ECOG PS na loš ishod AML-a [23].

Takođe, rezultati dobijeni analizom uticaja HCT-CI na OS pokazali su statističku značajnost u našoj studiji (p = 0,040), što je u skladu sa rezultatima drugih studija [10,21,25,26]. U studiji sprovedenoj na Klinici za hematologiju Kliničkog centra Srbije, 2011. godine, koja se bavila ispitivanjem HCT-CI kao prog nostičkog faktora za OS i koja je pomagala u donošenju odluke o primeni intenzivne terapije kod starijih pacijenata sa AML-om, pokazana je statistički značajna povezanost između HCT-CI ≥ 3 i OS [7]. Međutim, uticaj HCT-CI na postizanje KR, ranu smrtnost i pojavu relapsa, u našoj studiji, nije dokazan.

Povišene vrednosti LDH (LDH > 450 U/I) su se poka zale kao značajni prog nostički faktor OS (p = 0,044) u našoj studiji, što je u skladu sa podacima iz ranije objavljenih studija [6,21,25]. Uticaj povišene vrednosti LDH u serumu na postizanje KR, ranu smrtnost i pojavu relapsa, nismo dokazali. U prospektivnoj AML96 studiji, koja je obuhvatila 909 pacijenata obolelih od AML-a, vrednosti LDH > 700 U/I pokazale su značajan uticaj na kraće OS [9]. Takođe, u studiji sprovedenoj na Klinici za hematologiju Kliničkog centra Srbije, 2011. godine, koja se bavila ispitivanjem komorbiditeta kao prog nostičkog faktora za OS obolelih od AML-a, pokazan je nepovoljan uticaj povišenih vrednosti LDH kako na OS, tako i na KR [7].

Pacijenti sa intermedijarnim i nepovoljnim rizikom, prema ELN klasifikaciji, bili su zastupljeniji u našoj studiji, u odnosu na pacijente sa povoljnim rizikom (61,7% i 33% naspram 5,3%), što je u skladu sa literaturnim podacima [7]. Međutim, u ovoj studiji nije pokazana statistička povezanost nepovoljnog stepena rizika prema ELN-u sa lošijim vrednostima OS i KR, češćom pojavom relapsa i češćom ranom smrtnošću, što se može

the effect of unfavorable ECOG PS on higher mortality, achieving CR and shorter OS, in patients older than 65 years, has been proven [7,11]. Our study showed that ECOG PS had a statistically significant effect on the occurrence of early mortality (p = 0.030). The effect of ECOG PS on the following: achieving CR, early mortality, and the occurrence of relapse, was not proven in our study. In the study carried out by the Southwestern Oncology Group (SWOG), where patients aged ≥ 56 years were analyzed, a significant effect of unfavorable ECOG PS on unfavorable outcome of AML was demonstrated [23].

Also, the results obtained from the analysis of the effect of HCT-CI on OS showed statistical significance in our study (p = 0.04), which is in keeping with the results of other studies [10,21,25,26]. In a study carried out at the Clinic for Hematology of the Clinical Center of Serbia, in 2011, which analyzed HCT-CI as a prognostic factor of OS, and which assisted in making decisions on the application of intensive therapy in elderly patients with AML, a statistically significant connection between HCT-CI > 3 and OS was proven [7]. However, the effect of HCT-CI on the following: achieving CR, early mortality, the occurrence of relapse, was not proven in our study.

In our study, elevated levels of LDH (LDH >450 U/I) proved to be a significant prognostic marker of OS (p = 0.044), which is in keeping with data from previous studies [6,21,25]. The effect of elevated LDH serum levels on CR, early mortality, and the occurrence of relapse, were not proven in our study. In the prospective AML96 study, involving 909 patients suffering from AML, the values of LDH >700 U/I showed a significant effect on shorter OS [9]. Also, in a study carried out at the Clinic for Hematology of the Clinical Center of Serbia, in 2011, which analyzed comorbidities as a prognostic marker of the OS of patients suffering from AML, a negative effect of elevated LDH levels on both OS and CR was demonstrated [7].

There were more patients with intermediate and unfavorable risk levels, according to the ELN classification, as compared to the patients with a favorable risk level (61.7% and 33% vs. 5.3%), in our study, which is in keeping with data that can be found in literature [7]. However, the study did not demonstrate a statistical connection between unfavorable risk levels, according to ELN, and unfavorable values of OS and CR, a more frequent occurrence of relapse, and a more frequent occurrence of early mortality, which can be explained by the small number of patients in our study. A study carried out by the American Society of Hematology indicates the possible connection between unfavorable karyotype, i.e., risk level, and a more unfavorable outcome, due to a greater association of resistant disease with the said karyotype [11].
objasniti malim brojem pacijenata u studiji. Studija Američkog udruženja hematologa ukazuje na moguću povezanost nepovoljnog kariotipa, odnosno stepena rizika, sa lošijim ishodom, usled veće udruženosti rezistentne bolesti sa navedenim kariotipom [11].

*P* NPM1/FLT3 status određivan je kod 19 pacijenata u našoj studiji. Kod četiri pacijenta (21,1%) sa NPM1-/FLT3-TD+ statusom, zbog malog broja pacijenata nismo mogli da dokažemo prognostički značaj u pogledu OS, KR, rane smrtnosti i relapsa. U prospektnoj AML96 studiji, koja je obuhvatala 909 pacijenata, analiza 663 pacijenta na NPM1 i FLT3 status pokazala je da postoji statistički značajna povezanost pozitivnog NPM1, ali ne i pozitivnog FLT-3ITD statusa, sa boljim preživljavanjem [9].

Analizom svih pacijenata uključenih u studiju, otkriveno je da se AML češće javljala kao *de novo* bolest, u odnosu na progresiju prethodno postojeće hematološke bolesti (86,2% naspram 13,8%). Ispitivanjem uticaja sekundarni nastale AML na OS, KR, ranu smrtnost i pojavu relapsa, nismo registrujali povezanost, možda je zbog malog broja pacijenata. U SWOG studiji, zastupljenost sekundarnih AML-a kretala se od 22% do 24% [23]. U nemačkoj AML HD98-B studiji, zastupljenost sekundarnih AML-a iznosila je 33% [22].

U našoj studiji, bilo je više pacijenata u grupi sa brojem Le < 30x10^9/l u odnosu na grupu sa brojem Le ≥ 30x10^9/l (71% naspram 29%), pri čemu veći broj Le u krvi nije imao uticaja na OS, KR, ranu smrtnost i pojavu relapsa.

Nije izvršeno istraživanje na uticaj većeg broja Le na ishod AML-a, dok druge studije negiraju navedenu povezanost. Studija sprovedena na Klinici za Hematologiju, koja se bavila ispitivanjem komorbiditeta kao prognostičkog faktora za OS kod starijih pacijenata sa AML-om, ukazala je na značajnu povezanost povišenog broja Le (Le > 30x10^9/l) i OS [7].

Nije izvršeno istraživanje na uticaj većeg broja Le na ishod AML-a, dok druge studije negiraju navedenu povezanost. Studija sprovedena na Klinici za Hematologiju, koja se bavila ispitivanjem komorbiditeta kao prognostičkog faktora za OS kod starijih pacijenata sa AML-om, ukazala je na značajnu povezanost povišenog broja Le (Le > 30x10^9/l) i OS [7].

*Zaključak*

Kao zaključak ovog istraživanja možemo da istaknemo da opšte funkcionalne kriterije pacijenta izražene putem *ECOG* skore, zatim prisustvo komorbiditeta označeno putem *HCT-CI* skore, kao i povišene vrednosti LDH u serumu, imaju uticaj na OS starijih pacijenata obolelih od AML-a. Međutim, naša studija nije dokazala značaj ovih, kao ni drugih parametara koje smo pratili, za učestalost KR, relapsa i rane smrtnosti.

*Sukob interesa:* Nije prijavljen.

---

**Conflict of interest:** None declared.
LITERATURA / REFERENCES

1. Janković G. Akutna mijeloblastna leukemija. In: Ćolović M, Janković G. Maligne bolesti krvi. Beograd, Zavod za udžbenike i nastavna sredstva, 1999: 87-119.

2. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al. SEER Cancer Statistics Review, 1975-2005. SEER Database, National Cancer Institute; 2009.

3. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wörmann B, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999 Nov;17(11):3569-76.

4. Stone RM. The difficult problem of acute myeloid leukemia in older adult. CA Cancer J Clin. 2002;52:363-71.

5. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006 May 1

6. Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006 Mar 1;106(5):1090-8.

7. Djunic I, Virijevic M, Novkovic A, Djurasinovic V, Colovic N, Vidovic A, et al. Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia. Med Oncol. 2012 Jun;29(2):1077-81.

8. Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, et al. Survival of elderly patients with acute myeloid leukemia. Haematologica. 2004 Mar;89(3):296-302.

9. Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010 Aug 12;116(6):971-8.

10. Mal fuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008 Dec;93(12):1806-13.

11. Erba HP. Prognostic factors in elderly patients withAML and the implications for treatment. Hematology Am Soc Hematol Educ Program.2007:420-8.

12. Wedding U, Höffken K. Therapy of acute myeloid leukemia in the elderly patient. Z Gerontol Geriatr.2001;34(4):269-76.

13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55.

14. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014 Oct 10;32(29):3249-56.

15. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21;115(3):453-74.

16. Arber DA, Brunning RD, Le Beau, et al. MM WHO classification. IARC. Lyon, 2008;p.110-46.

17. Béné MC, Nebe T, Bettelheim P, Baldini B, Bumbea H, Kern W, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia. 2011 Apr;25(4):567-74.

18. International System for Human Cytogenetic Nomenclature (ISCN). Recommendations for the International Standing Committee on Human Cytogenetic Nomenclature. Memphis, Tennessee, USA, 1994.

19. Cheson BD, Bennett JMM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9.

20. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011 Nov 20;29(33):4417-21.

21. Breccia M, Frustaci AM, Cannella L, Stefanizzi C, Latagliata R, Cartoni C, et al. Comorbidities and FL/T3-ID abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukemia patients. Hematol Oncol. 2009 Sep;27(3):148-53.

22. Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K, et al. For the German-Austrian Study Group. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006 Nov 15;108(10):3280-8.

23. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006 May 1;107(9):3481-5.

24. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002 Jul 22;162(14):1597-603.

25. Etienne A, Esterni B, Charbonnier A, Mozzi ficonacci MJ, Arnoletti C, Coso D, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007 Apr 1;109(7):1376-83.

26. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007 Feb;136(4):624-7.